var data={"title":"Penicillin G benzathine (long-acting intramuscular): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Penicillin G benzathine (long-acting intramuscular): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6742?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=penicillin-g-benzathine-long-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Penicillin G benzathine (long-acting intramuscular): Patient drug information&quot;</a> and <a href=\"topic.htm?path=penicillin-g-benzathine-long-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin G benzathine (long-acting intramuscular): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7272304\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Not for intravenous (IV) use. Do not inject IV or admix with other IV solutions. There have been reports of inadvertent IV administration of penicillin G benzathine that has been associated with cardiorespiratory arrest and death. Prior to administration of this drug, carefully read the Administration and Dosage section.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207570\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bicillin L-A</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663226\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bicillin L-A</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207608\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207574\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Usual dosage range:</b> IM: 1.2 to 2.4 million units as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Upper respiratory infection, group A streptococci:</b> IM: 1.2 million units as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Secondary prevention of glomerulonephritis:</i> 1.2 million units every 4 weeks or 600,000 units twice monthly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Secondary prevention of rheumatic fever:</i> 1.2 million units every 3 to 4 weeks or 600,000 units twice monthly   (Gerber, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis, group A streptococci (IDSA guidelines):</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute treatment:</i> 1.2 million units as a single dose (Shulman, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic carrier treatment:</i> 1.2 million units as a single dose in combination with oral rifampin (Shulman, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis (CDC [Workowski 2015]):</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary, Secondary, Early Latent (&lt;1 year duration):</i> 2.4 million units as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Late Latent, Latent with unknown duration, or Tertiary Syphilis (with normal CSF examination):</i> 2.4 million units once weekly for 3 doses </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurosyphilis (including Ocular Syphilis):</i> Not indicated for use; aqueous penicillin G IV is preferred initial therapy (refer to Penicillin G Parenteral/Aqueous monograph for dosing)  but consideration may be given to administering 2.4 million units IM once weekly for 3 weeks following IV treatment to provide a comparable total duration of therapy as latent syphilis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Yaws, bejel, and pinta:</b> IM: 1.2 million units as a single dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207591\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=penicillin-g-benzathine-long-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin G benzathine (long-acting intramuscular): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Usual dosage range:</b> IM: 50,000 units/kg as a single dose (maximum: 2.4 million units)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Upper respiratory infection, group A streptococci (eg, pharyngitis):</b> Infants and Children: IM: Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;27.3 kg: 300,000 to 600,000 units as a single dose. Manufacturer labeling does not provide specific recommendation for children &ge;27.3 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For older children, a dose of 900,000 units as a single dose is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary prevention of rheumatic fever:</b> Infants and Children:  IM: &le;27 kg: 600,000 units as a single dose; &gt;27 kg: 1.2 million units as a single dose (Gerber, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary prevention of rheumatic fever:</b> Infants and Children:  IM: &le;27 kg: 600,000 units every 3-4 weeks; &gt;27 kg: 1.2 million units every 3 to 4 weeks (Gerber, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis, group A streptococci (IDSA guidelines):</b> Infants and Children: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute treatment:</i> &lt;27 kg: 600,000 units as a single dose; &ge;27 kg: 1.2 million units as a single dose (Shulman, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic carrier treatment:</i> &lt;27 kg: 600,000 units as a single dose (in combination with oral rifampin); &ge;27 kg: 1.2 million units as a single dose (in combination with oral rifampin) (Shulman, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis (off-label population; CDC [Workowski 2015]):</b> IM: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary, Secondary, and Early Latent (&lt;1 year duration):</i>  Infants and Children: 50,000 units/kg/dose as a single injection (maximum: 2.4 million units/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Late Latent:</i> Infants and Children: 50,000 units/kg/dose every week for 3 doses (maximum: 2.4 million units/dose) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207575\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22154798\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22154799\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207553\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bicillin L-A: 600,000 units/mL (1 mL); 1,200,000 units/2 mL (2 mL); 2,400,000 units/4 mL (4 mL) [contains methylparaben, propylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207537\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207556\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Warm to room temperature before administration to lessen the pain associated with injection. Administer by deep IM injection in the upper outer quadrant of the buttock; in children &lt;2 years of age, IM injections should be made into the midlateral muscle of the thigh, not the gluteal region. Do not inject near an artery or a nerve; permanent neurological damage or gangrene may result.  When doses are repeated, rotate the injection site. <b>Do not administer IV, intra-arterially, or SubQ.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207554\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute glomerulonephritis:</b> Prophylaxis (secondary) in patients with a history of acute glomerulonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections:</b> Treatment of mild to moderate upper respiratory tract infections caused by streptococci susceptible to low, prolonged serum concentrations of penicillin G</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatic fever and chorea:</b> Prophylaxis (secondary) of rheumatic fever and/or chorea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatic heart disease:</b> Prophylaxis (secondary) in patients with rheumatic heart disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis and other venereal diseases:</b> Treatment of syphilis, yaws, bejel, and pinta</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207616\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Penicillin may be confused with penicillamine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bicillin may be confused with Wycillin </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Penicillin G benzathine may only be administered by deep intramuscular injection; intravenous administration of penicillin G benzathine has been associated with cardiopulmonary arrest and death.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bicillin C-R (penicillin G benzathine and penicillin G procaine) may be confused with Bicillin L-A (penicillin G benzathine). Penicillin G benzathine is the only product currently approved for the treatment of syphilis. Administration of penicillin G benzathine and penicillin G procaine combination instead of Bicillin L-A may result in inadequate treatment response. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207544\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cerebrovascular accident, hypotension, palpitations, syncope, tachycardia, vasodilatation, vasospasm, vasodepressor syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, coma, confusion, dizziness, drowsiness, euphoria, fatigue, headache, localized warm feeling, nervousness, neurologic abnormality (neurogenic bladder), numbness, pain, seizure, transverse myelitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, gangrene of skin or other tissue, pallor, skin mottling, skin ulceration at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Bloody stools, intestinal necrosis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, impotence, priapism, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Local hemorrhage (at injection site), lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Jarisch-Herxheimer reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Abscess at injection site, atrophy at injection site, bruising at injection site, cellulitis at injection site, localized edema (at injection site), inflammation at injection site, injection site reaction (neurovascular damage), pain at injection site, residual mass at injection site, tissue necrosis at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthropathy, exacerbation of arthritis, periosteal disease (periostitis), rhabdomyolysis, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blindness, blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, myoglobinuria, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cyanosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207559\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to penicillin(s) or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207541\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity (including cephalosporins), history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Serious anaphylactic reactions require immediate emergency treatment with epinephrine, oxygen, intravenous steroids and airway management (including intubation) as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Syphilis/neurosyphilis use: CDC and AAP do not currently recommend the use of penicillin G benzathine for the initial treatment regimen for congenital syphilis or neurosyphilis due to reported treatment failures and lack of published clinical data on its efficacy (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate administration: <b>[US Boxed Warning]: Not for intravenous use; cardiopulmonary arrest and death have occurred from inadvertent IV administration.</b> Administer by deep IM injection only. Quadriceps femoris fibrosis and atrophy have been reported after repeated IM injections of penicillin preparations into the anterolateral thigh. Injection into or near an artery or nerve could result in severe neurovascular damage or permanent neurological damage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use only for treatment of infections due to penicillin G sensitive gram positive organisms, few gram-negative organisms such as <i>Neisseria gonorrhoeae</i>, and some anaerobes and spirochetes. Use only for infections susceptible to the low and very prolonged serum concentrations of benzathine penicillin G.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299839\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207546\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9551&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720604\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Penicillin G benzathine crosses the placenta (Nathan 1993; Weeks 1997). Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G is the drug of choice for treatment of syphilis during pregnancy (CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5694831\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Soluble penicillin G is excreted in breast milk. The manufacturer recommends that caution be exercised when administering penicillin to nursing women. Nondose-related effects could include modification of bowel flora and allergic sensitization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207551\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs and symptoms of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207540\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207558\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 1 to 4 weeks (dose dependent); larger doses result in more sustained levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Slow </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Minimal concentrations attained in CSF with inflamed or uninflamed meninges; highest levels in the kidney; lesser amounts in liver, skin, intestines</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein Binding: ~60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Within 12 to 24 hours; serum levels are usually detectable for 1 to 4 weeks depending on the dose; larger doses result in more sustained levels rather than higher levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Excreted by renal tubular excretion; penicillin G is detected in urine for up to 12 weeks after a single IM injection; renal clearance is delayed in neonates, young infants, and patients with impaired renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207561\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Bicillin L-A Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600000 units/mL (1 mL): $109.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200000 units/2 mL (2 mL): $188.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2400000 units/4 mL (4 mL): $386.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207562\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bencelin (MX);</li>\n      <li>Benzapen (PH, TR);</li>\n      <li>Benzetacil (BR, ES, GR, MX);</li>\n      <li>Benzetacil L.A. (PE, PY);</li>\n      <li>Benzibiotic (LK);</li>\n      <li>Bepeben (BR);</li>\n      <li>Bicillin G (JP);</li>\n      <li>Bicillin L-A (AU, NZ);</li>\n      <li>Debecylina (PL);</li>\n      <li>Deposilin (TR);</li>\n      <li>Extencilline (HR);</li>\n      <li>Indopen (PY);</li>\n      <li>Lentocilin-S (PT);</li>\n      <li>Leomypen (DK);</li>\n      <li>Longacillin (IN);</li>\n      <li>Mycin (KR);</li>\n      <li>Noraben (HK);</li>\n      <li>Pebenzatil (UY);</li>\n      <li>Pen Di Ben (AR);</li>\n      <li>Penadur (BE, CH, LU);</li>\n      <li>Penadur - LA (BB, BM, BS, BZ, GY, JM, PR, SR, TT);</li>\n      <li>Penadur LA (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Pencom (IN);</li>\n      <li>Pendepon (CZ);</li>\n      <li>Pendiben L-A (MX);</li>\n      <li>Pendysin (DE);</li>\n      <li>Penidural (NL);</li>\n      <li>Penidure (IN);</li>\n      <li>Penilente (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Penilente LA (ZA);</li>\n      <li>Penzathine (KR);</li>\n      <li>Retarpen (AT, BH, CY, CZ, EG, HR, IL, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SG, SY, TH, UA, UY, YE);</li>\n      <li>Retarpen LA (AE);</li>\n      <li>Tardocillin (DE);</li>\n      <li>Terbocyl (PE);</li>\n      <li>Unicil L-A (MX);</li>\n      <li>Zalpen (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bicillin L-A (penicillin G benzathine) [prescribing information]. New York, NY: Pfizer; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Collart P, Poitevin M, Milovanovic A, et al, &ldquo;Kinetic Study of Serum Penicillin Concentrations After Single Doses of Benzathine and Benethamine Penicillins in Young and Old People,&rdquo; <i>Br J Vener Dis</i>, 1980, 56(6):355-62. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/7448577/pubmed\" target=\"_blank\" id=\"7448577\">7448577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al, &ldquo;Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,&rdquo; <i>Circulation</i>, 2009, 119(11):1541-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan EL, Berrios X, Speth J, et al, &ldquo;Pharmacokinetics of Benzathine Penicillin G: Serum Levels During the 28 Days After Intramuscular Injection of 1,200,000 Units,&rdquo; <i>J Pediatr</i>, 1989, 115(1):146-50. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/2738782/pubmed\" target=\"_blank\" id=\"2738782\">2738782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nathan L, Bawdon RE, Sidawi JE, Stettler RW, McIntire DM, Wendel GD Jr. Penicillin levels following the administration of benzathine penicillin G in pregnancy. <i>Obstet Gynecol</i>. 1993;82(3):338-342.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/8355931/pubmed\" target=\"_blank\" id=\"8355931\">8355931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weeks JW, Myers SR, Lasher L, Goldsmith J, Watkins C, Gall SA. Persistence of penicillin G benzathine in pregnant group B streptococcus carriers. <i>Obstet Gynecol</i>. 1997;90(2):240-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/9241301/pubmed\" target=\"_blank\" id=\"9241301\">9241301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9551 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7272304\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F207570\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663226\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F207608\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F207574\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F207591\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F207575\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22154798\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22154799\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F207553\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F207537\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F207556\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F207554\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F207616\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F207544\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F207559\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F207541\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299839\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F207546\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720604\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5694831\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F207551\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F207540\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F207558\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F207561\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F207562\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9551|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=penicillin-g-benzathine-long-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">Penicillin G benzathine (long-acting intramuscular): Patient drug information</a></li><li><a href=\"topic.htm?path=penicillin-g-benzathine-long-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">Penicillin G benzathine (long-acting intramuscular): Pediatric drug information</a></li></ul></div></div>","javascript":null}